Tempus is a data-driven precision medicine company bringing the power of data and artificial intelligence to healthcare. Tempus is a technology company advancing precision medicine through the ...
Tempus AI announced a collaboration with the Institute for Follicular Lymphoma Innovation. The goal of the collaboration is to advance targeted therapy development for follicular lymphoma by ...
Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...
Hosted on MSN1mon
Tempus AI stock price is not cheap: is it a good buy?Tempus AI is seeing strong growth as companies remain interested in the AI industry. Its annual revenue has jumped from $62.1 million in 2019 to over $531 million in the last financial year.
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday ...
CHICAGO, February 18, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its ...
Tempus AI, Inc. Class A (TEM – Research Report) received a Hold rating and price target from William Blair analyst Andrew Brackmann today. The company’s shares closed yesterday at $89.44 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback